Concomitant osimertinib and antituberculosis therapy in an elderly patient with EGFR-mutated lung cancer and pulmonary tuberculosis: A case report

Hiroaki Matsuura; Hisao Higo; Tadahiro Kuribayashi; Akihiko Tamaoki; Takamasa Nakasuka; Mari Uno; Go Makimoto; Kiichiro Ninomiya; Masanori Fujii; Kammei Rai; Eiki Ichihara; Katsuyuki Hotta; Nobuaki Miyahara; Masahiro Tabata; Yoshinobu Maeda; Katsuyuki Kiura; Kadoaki Ohashi

doi:10.1111/1759-7714.15324

Concomitant osimertinib and antituberculosis therapy in an elderly patient with EGFR-mutated lung cancer and pulmonary tuberculosis: A case report

Hiroaki Matsuura, Hisao Higo, Tadahiro Kuribayashi, Akihiko Tamaoki, Takamasa Nakasuka, Mari Uno, Go Makimoto, Kiichiro Ninomiya, Masanori Fujii, Kammei Rai, Eiki Ichihara, Katsuyuki Hotta, Nobuaki Miyahara, Masahiro Tabata, Yoshinobu Maeda, Katsuyuki Kiura, Kadoaki Ohashi

University Hospital

Research output: Contribution to journal › Article › peer-review

1 Citation (Scopus)

Abstract

The concurrent incidence of lung cancer and tuberculosis is expected to escalate due to the projected growth in the older population. Combination therapy with osimertinib and antituberculosis drugs has not been well-established. We report a case of successful treatment involving the concomitant administration of osimertinib and antituberculosis drugs in an older patient, an 89-year-old female, diagnosed with epidermal growth factor receptor (EGFR)-mutant lung cancer and pulmonary tuberculosis. Accumulating evidence is warranted to develop an optimal treatment strategy for patients with lung cancer and tuberculosis.

Original language	English
Journal	Thoracic Cancer
DOIs	https://doi.org/10.1111/1759-7714.15324
Publication status	Accepted/In press - 2024

Keywords

case report
EGFR-mutated lung cancer
osimertinib
pulmonary tuberculosis
rifampicin

ASJC Scopus subject areas

Oncology
Pulmonary and Respiratory Medicine

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1111/1759-7714.15324

Cite this

Matsuura, H., Higo, H., Kuribayashi, T., Tamaoki, A., Nakasuka, T., Uno, M., Makimoto, G., Ninomiya, K., Fujii, M., Rai, K., Ichihara, E., Hotta, K., Miyahara, N., Tabata, M., Maeda, Y., Kiura, K., & Ohashi, K. (Accepted/In press). Concomitant osimertinib and antituberculosis therapy in an elderly patient with EGFR-mutated lung cancer and pulmonary tuberculosis: A case report. Thoracic Cancer. https://doi.org/10.1111/1759-7714.15324

Matsuura, H, Higo, H, Kuribayashi, T, Tamaoki, A, Nakasuka, T, Uno, M, Makimoto, G , Ninomiya, K , Fujii, M , Rai, K , Ichihara, E , Hotta, K , Miyahara, N , Tabata, M , Maeda, Y, Kiura, K & Ohashi, K 2024, 'Concomitant osimertinib and antituberculosis therapy in an elderly patient with EGFR-mutated lung cancer and pulmonary tuberculosis: A case report', Thoracic Cancer. https://doi.org/10.1111/1759-7714.15324

@article{f29eab99acf4463f8a187c79e4aa5839,

title = "Concomitant osimertinib and antituberculosis therapy in an elderly patient with EGFR-mutated lung cancer and pulmonary tuberculosis: A case report",

abstract = "The concurrent incidence of lung cancer and tuberculosis is expected to escalate due to the projected growth in the older population. Combination therapy with osimertinib and antituberculosis drugs has not been well-established. We report a case of successful treatment involving the concomitant administration of osimertinib and antituberculosis drugs in an older patient, an 89-year-old female, diagnosed with epidermal growth factor receptor (EGFR)-mutant lung cancer and pulmonary tuberculosis. Accumulating evidence is warranted to develop an optimal treatment strategy for patients with lung cancer and tuberculosis.",

keywords = "case report, EGFR-mutated lung cancer, osimertinib, pulmonary tuberculosis, rifampicin",

author = "Hiroaki Matsuura and Hisao Higo and Tadahiro Kuribayashi and Akihiko Tamaoki and Takamasa Nakasuka and Mari Uno and Go Makimoto and Kiichiro Ninomiya and Masanori Fujii and Kammei Rai and Eiki Ichihara and Katsuyuki Hotta and Nobuaki Miyahara and Masahiro Tabata and Yoshinobu Maeda and Katsuyuki Kiura and Kadoaki Ohashi",

note = "Publisher Copyright: {\textcopyright} 2024 The Authors. Thoracic Cancer published by John Wiley & Sons Australia, Ltd.",

year = "2024",

doi = "10.1111/1759-7714.15324",

language = "English",

journal = "Thoracic Cancer",

issn = "1759-7706",

publisher = "John Wiley and Sons Inc.",

}

TY - JOUR

T1 - Concomitant osimertinib and antituberculosis therapy in an elderly patient with EGFR-mutated lung cancer and pulmonary tuberculosis

T2 - A case report

AU - Matsuura, Hiroaki

AU - Higo, Hisao

AU - Kuribayashi, Tadahiro

AU - Tamaoki, Akihiko

AU - Nakasuka, Takamasa

AU - Uno, Mari

AU - Makimoto, Go

AU - Ninomiya, Kiichiro

AU - Fujii, Masanori

AU - Rai, Kammei

AU - Ichihara, Eiki

AU - Hotta, Katsuyuki

AU - Miyahara, Nobuaki

AU - Tabata, Masahiro

AU - Maeda, Yoshinobu

AU - Kiura, Katsuyuki

AU - Ohashi, Kadoaki

PY - 2024

Y1 - 2024

N2 - The concurrent incidence of lung cancer and tuberculosis is expected to escalate due to the projected growth in the older population. Combination therapy with osimertinib and antituberculosis drugs has not been well-established. We report a case of successful treatment involving the concomitant administration of osimertinib and antituberculosis drugs in an older patient, an 89-year-old female, diagnosed with epidermal growth factor receptor (EGFR)-mutant lung cancer and pulmonary tuberculosis. Accumulating evidence is warranted to develop an optimal treatment strategy for patients with lung cancer and tuberculosis.

AB - The concurrent incidence of lung cancer and tuberculosis is expected to escalate due to the projected growth in the older population. Combination therapy with osimertinib and antituberculosis drugs has not been well-established. We report a case of successful treatment involving the concomitant administration of osimertinib and antituberculosis drugs in an older patient, an 89-year-old female, diagnosed with epidermal growth factor receptor (EGFR)-mutant lung cancer and pulmonary tuberculosis. Accumulating evidence is warranted to develop an optimal treatment strategy for patients with lung cancer and tuberculosis.

KW - case report

KW - EGFR-mutated lung cancer

KW - osimertinib

KW - pulmonary tuberculosis

KW - rifampicin

UR - http://www.scopus.com/inward/record.url?scp=85192158307&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85192158307&partnerID=8YFLogxK

U2 - 10.1111/1759-7714.15324

DO - 10.1111/1759-7714.15324

M3 - Article

C2 - 38698706

AN - SCOPUS:85192158307

SN - 1759-7706

JO - Thoracic Cancer

JF - Thoracic Cancer

ER -

Concomitant osimertinib and antituberculosis therapy in an elderly patient with EGFR-mutated lung cancer and pulmonary tuberculosis: A case report

Abstract

Keywords

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this